Indian multinational pharmaceutical company making generic and specialty medicines, a leader in India's anti-infectives market.
alkemlabs.comFounded
1973 (incorporated 8 August 1973)
Headquarters
Alkem House, Lower Parel, Mumbai 400013, India
Industry
Pharmaceuticals (generics and specialty)
Employees
About 24,000CEO
Vikas Gupta
Revenue (FY26)
About Rs 14,712 crore (approx US$1.7 billion)
Market Cap
About Rs 67,894 crore (approx US$8 billion)
Listed on
NSE: ALKEM, BSE: 539523
CIN
L00305MH1973PLC174201
Website
alkemlabs.comAlkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Founded in 1973 by brothers Samprada Singh and Basudeo Narayan Singh, and incorporated on 8 August 1973, the company develops, manufactures, and sells generic and specialty pharmaceutical and nutraceutical products. It's one of India's largest drugmakers and holds a leading position in the domestic anti-infectives segment, with brands that include Clavam and Pan-D.
The company is listed on both the NSE (ticker ALKEM) and the BSE (code 539523) and carries a market capitalization of roughly Rs 67,894 crore. For fiscal year 2026, Alkem reported consolidated revenue of about Rs 14,712 crore. It ranks among the top five companies in India's domestic formulation market by share.
Alkem operates 21 manufacturing facilities, with 19 in India and 2 in the United States, and five sites hold US FDA, TGA, and UK MHRA approvals. The company employs roughly 24,000 people. Its senior leadership includes Executive Chairman Basudeo N. Singh, Chief Executive Officer Vikas Gupta, Managing Director Sandeep Singh, and Chief Financial Officer Nitin Agrawal.
Executive Chairman (co-founder)
Chief Executive Officer (since September 2023)
Managing Director
Chief Financial Officer (since February 2024)
Interview experience
7 out of 10 (Favourable)
Interview difficulty
Medium (5 out of 10)
Interview process length
About a week (most common)
Browse question banks by role, round and company, with answers and examples.
Estimated average
₹18,74,427 to ₹24,75,177 / year (avg ₹21,53,959)
3 Salaries submitted
Estimated average
₹4,06,000 to ₹21,64,000 / year (avg ₹11,13,626)
5 Salaries submitted
Survey-based average
₹4,51,000 / year avg base (avg bonus ₹31,000)
22 Salaries submitted
See how your pay compares and find roles that match your target.
Daman • Full-time
Mumbai • Full-time
Mumbai • Full-time
Mumbai • Full-time
Navi Mumbai • Full-time
Navi Mumbai • Full-time
Free guides to AI video screens, coding tests and how scoring works.
July 17, 2026
Alkem completes acquisition of Swiss medical device firm Occlutech
Alkem finalised its acquisition of a 51 to 55% majority stake in Occlutech Holding AG, a Swiss maker of minimally invasive cardiac implants, through subsidiary Alkem Medtech. The deal marks Alkem's push into the global medical devices sector.
#Acquisition #MedicalDevices #Occlutech
View postJune 30, 2026
Alkem to host institutional investor Sprucegrove in Mumbai
Alkem scheduled a one-on-one meeting with Sprucegrove Investments on July 6, 2026 in Mumbai to discuss its operations and performance. The SEBI-compliant disclosure was filed on June 29, 2026 by company secretary Manish Narang.
#InvestorRelations #SEBI
View postJune 1, 2026
Alkem's semaglutide takes 11% market share; Tolvaptan launch pulled forward
Alkem's semaglutide, launched in March 2026, captured about 11% unit market share in its initial reporting period. Management flagged an early U.S. launch of gJynarque (Tolvaptan) around September to October 2026, ahead of prior estimates.
#GLP1 #ProductLaunch #USMarket
View postMay 29, 2026
Alkem posts record FY26 EBITDA; Q4 revenue up 14.6%
Alkem reported Q4 FY26 revenue of Rs 36,033 million, up 14.6% YoY, with EBITDA rising 32.2% to Rs 5,174 million, though net profit fell 22.7% to Rs 2,365 million on exceptional items. FY26 revenue grew 13.5% to Rs 147,123 million and EBITDA hit a record Rs 30,052 million.
#Q4FY26 #Earnings #PharmaIndia
View postFebruary 13, 2026
Alkem Q3 FY26 revenue up 11%; signs binding deal for Occlutech
Alkem posted Q3 FY26 revenue of Rs 37,368 million, up 11% YoY, led by international sales rising 26.6% to Rs 12,157 million. The company executed a binding agreement to buy a majority stake in Occlutech to build a global medical devices footprint.
#Q3FY26 #Earnings #Occlutech
View postAlkem is an Indian multinational pharmaceutical company that develops, manufactures, and sells generic and specialty medicines and nutraceuticals. It's a leader in India's domestic anti-infectives segment, with brands like Clavam and Pan-D.
Last updated:
